HANMI PHARM CO LTD has a total of 194 patent applications. It increased the IP activity by 21.0%. Its first patent ever was published in 2001. It filed its patents most often in Australia, Taiwan and Singapore. Its main competitors in its focus markets pharmaceuticals, biotechnology and organic fine chemistry are HASUMI KENICHIRO, JUVENTAS THERAPEUTICS INC and TILLOTTS PHARMA AG.
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Organic fine chemistry | |
#4 | Foods and drinks | |
#5 | Macromolecular chemistry and polymers | |
#6 | Machines |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Heterocyclic compounds | |
#5 | Microorganisms | |
#6 | Enzymes | |
#7 | Organic chemistry methods | |
#8 | Special macromolecular compounds | |
#9 | Unspecified technologies | |
#10 | Sugars |
# | Name | Total Patents |
---|---|---|
#1 | Kwon Se Chang | 60 |
#2 | Jung Sung Youb | 58 |
#3 | Woo Jong Soo | 47 |
#4 | Park Jae Hyun | 42 |
#5 | Kim Yong Il | 38 |
#6 | Choi In Young | 37 |
#7 | Lim Hyung Kyu | 18 |
#8 | Kim Dae Jin | 18 |
#9 | Suh Kwee Hyun | 18 |
#10 | Bae Sung Min | 18 |
Publication | Filing date | Title |
---|---|---|
AU2019203034B1 | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | |
AU2018341729A1 | Pharmaceutical composition including multi-unit spheroidal tablet containing esomeprazole and spheroidal pharmaceutically acceptable salt thereof, and method of preparing the pharmaceutical composition | |
AU2017244269A1 | Composite capsule preparation containing tadalafil and tamsulosin and having improved stability and elution rate | |
TW201718629A | A protein conjugate comprising multiple physiological polypeptides and an immunoglobulin Fc region | |
TW201710288A | Novel insulin analogs | |
AU2015242657A1 | Method for improving solubility of protein and peptide by using immunoglobulin Fc fragment linkage | |
TW201442723A | A method of virus inactivation in composition comprising factor vii | |
TW201410704A | A liquid formulation of long-acting insulin and insulinotropic peptide |